Prevalencija VKORC1 alela u populaciji Republike Srpske, Bosna i Hercegovina

  • Vanja Vidović Faculty of Medicine, University of Banja Luka
  • Jelena Bećarević Center for Biomedical Research, Faculty of Medicine, University of Banja Luka
  • Žana Radić Savić Department of Medical Biochemistry, Faculty of Medicine, University of Banja Luka
  • Aljoša Marić
  • Stojko Vidović
  • Irina Milovac
  • Nela Maksimović
DOI: https://doi.org/10.5937/scriptamed54-43841
Ključne reči: VKORC1, aleli, distribucija, polimorfizam, warfarin

Sažetak


Background/Aim: Warfarin is one of the most common orally prescribed anticoagulant in patients with deep venous thrombosis, myocardial or cerebral infarctions. The main side effects of non-adequate dose of these drugs are prolonged peripheral or internal bleeding. VKORC1 1173C>T  polymorphism (rs9934438) is of particular importance, since carriers of non-wild type allele correlates with the lower dosage of warfarin therapy. Thus, the aim of the research was to determine the distribution of 1173C>T polymorphism in population of the Republic of Srpska, Bosnia and Herzegovina (RS) and to compare results with frequencies in other populations.

Methods: A total of 124 healthy participants of both genders were enrolled in the study, from all parts of the RS. Molecular genotyping was performed by real-time PCR, using drug metabolism assays according to the manufacturer’s instructions.

Results: Of the total number, 22 subjects (17.74 %) were genotyped as CC, 69 subjects (55.65 %) as CT and 33 subjects (26.61 %) as TT. The frequencies of alleles C and T were 45.18 % and 54.82 %, respectively. No statistical significance was found among allele distribution between genders (χ² = 0.236; p = 0.627). All observed genotype frequencies were in Hardy-Weinberg equilibrium. No statistical significance was observed among the frequency of minor T allele between presented findings and other European countries, besides Russia (p = 0.021).

Conclusion: This was the first study analysing the distribution of rs9934438 alleles in population of the RS. These findings will be helpful in better and more precise drug prescribing in patients who require anticoagulant therapy.

Reference

 

 

1.         Mandic D, Mandic S, Horvat V, Samardzìja M, Samardìja M. Vitamin K epoxide reductase complex 1 (VKORC1) gene polymorphisms in population of eastern Croatia. Coll Antropol 2013;37(4):1321–6.

2.         Oldenburg J, Marinova M, Müller-Reible C, Watzka M. The Vitamin K cycle. Vitam Horm 2008;78:35–62.

3.         Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006;79(4):291–302.

4.         Cavallari LH, Momary KM. Pharmacogenetics in cardiovascular diseases. In: Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. Amsterdam, Netherlands: Elsevier; 2018. p. 133–79.

5.         Makar-Ausperger K, Krželj K, Benčić ML, Aumiler MR, Turk VE, Božina N. Warfarin dosing according to the genotype-guided algorithm is most beneficial in patients with atrial fibrillation: A randomized parallel group trial. Ther Drug Monit 2018;40(3):362–8.

6.         Akdeniz CS, Cevik M, Canbolat IP, Yurdakul S, Cagatay P, Ciftci C, et al. The effects of and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients. Future Cardiol 2020;16(6):645–54.

7.         Li Y, Zhu J, Ding J. VKORC1-1639G/A and 1173 C/T Genetic Polymorphisms influence individual differences in warfarin maintenance dose. Genet Test Mol Biomarkers 2015;19(9):488–93.

8.         Kosaki K, Yamaghishi C, Sato R, Semejima H, Fuijita H, Tamura K, et al. 1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatr Cardiol 2006;27(6):685–8.

9.         Owen RP, Gong L, Sagreiya H, Klein TE, Altman RB. VKORC1 pharmacogenomics summary. Pharmacogenet Genomics 2010;20:642–4.

10.      Soltani Banavandi MJ, Satarzadeh N. Association between VKORC1 gene polymorphism and warfarin dose requirement and frequency of VKORC1 gene polymorphism in patients from Kerman province. Pharmacogenomics J 2020;20(4):574–8.

11.      Biswas M, Bendkhale SR, Deshpande SP, Thaker SJ, Kulkarni DV, Bhatia SJ, et al. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit. Indian Heart J 2018;70:S13–9.

12.      al Ammari M, AlBalwi M, Sultana K, Alabdulkareem IB, Almuzzaini B, Almakhlafi NS, et al. The effect of the VKORC1 promoter variant on warfarin responsiveness in the Saudi WArfarin Pharmacogenetic (SWAP) cohort. Sci Rep 2020 Jul 15;10(1):11613. doi: 10.1038/s41598-020-68519-9.

13.      Moreau C, Pautas E, Gouin-Thibault I, Golmard JL, Mahé I, Mulot C, et al. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: Accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes. J Thromb Haemost 2011 Apr;9(4):711-8.

14.      Lucia RD, di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105(2):645-9.

15.      Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V. The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 2006;95(5):782–7.

16.      Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005;94(4):773–9.

17.      Alzahrani AM, Ragia G, Hanieh H, Manolopoulos VG. Genotyping of CYP2C9 and VKORC1 in the arabic population of Al-Ahsa, Saudi Arabia. Biomed Res Int 2013;2013:315980. doi: 10.1155/2013/315980.

18.      Cadamuro J, Dieplinger B, Felder T, Kedenko I, Mueller T, Haltmayer M, et al. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. Eur J Clin Pharmacol 2010;66(3):253–60.

19.      Panchenko E, Kropacheva E, Dobrovolsky A, Titaeva E, Zemlyanskaya O, Trofimov D, et al. CYP2C9 and VKORC1 genotyping for the quality of long-standing warfarin treatment in Russian patients. Pharmacogenomics J 2020;20(5):687–94.

20.      Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: Proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007;63(12):1135–41.

21.      El Din MS, Amin DG, Ragab SB, Ashour EE, Mohamed MH, Mohamed AM. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: Proposal for a new dosing regimen. Int J Lab Hematol 2012;34(5):517–24.

22.      Au N, Rettie AE. Pharmacogenomics of 4-hydroxycoumarin anticoagulants. Drug Metab Rev 2008;40:355-75.

23.      Schwarz UI, Stein CM. Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. Clin Pharmacol Ther 2006;80(1):7–12.

24.      Nakai K, Tsuboi J, Okabayashi H, Fukuhiro Y, Oka T, Habano W, et al. Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics 2007;8(7):713–9.

25.      Vidovic S, Skrbic R, Stojiljkovic MP, Vidovic V, Becarevic J, Stoisavljevic-Satara S, et al. Prevalence of five pharmacologically most important CYP2C9 and CYP2C19 allelic variants in the population from the Republic of Srpska in Bosnia and Herzegovina. Arh Hig Rada Toksikol 2021:28;72(3):129–34.

26.      Theken KN, Lee CR, Gong L, Caudle KE, Formea CM, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and nonsteroidal anti-inflammatory drugs. Clin Pharmacol Ther 2020;1;108(2):191–200.

27.      Johnson JA, Caudle K, Gong L, Whirl-Carrillo M, Stein CM, Scott SA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin Pharmacol Ther 2017 Sep;102(3):397-404.

28.      McClain MR, Palomaki GE, Piper M, Haddow JE. A Rapid-ACCE review of CYP2C9 and VKORC1 alleles testing to inform warfarin dosing in adults at elevated risk for thrombotic events to avoid serious bleeding. Genet Med 2008;10(2):89–98.

29.      Li S, Zou Y, Wang X, Huang X, Sun Y, Wang Y, et al. Warfarin dosage response related pharmacogenetics in chinese population. PLoS One 2015 Jan 16;10(1):e0116463. doi: 10.1371/journal.pone.0116463.

30.      Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. Thromb Res 2014 Sep;134(3):537-44.

31.      31. Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. Thromb Res 2014 Sep;134(3):537-44.

32.      Social Science Statistics [Internet]. [Cited: 1-Jan-2021]. Available at: https://www.socscistatistics.com/tests/.>

Objavljeno
2023/06/24
Broj časopisa
Vol. 54 Br. 2 (2023): Q2/June 2023
Rubrika
Originalni naučni članak
Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).